NUCLEUS-SOFTWARE
5.10.2021 15:09:13 CEST | Business Wire | Press release
Opel Vauxhall Finance announces the going live in Spain of Nucleus Software’s flagship lending product, FinnOne. Nucleus Software is the leading provider of lending and transaction banking products and solutions to the global financial industry. Spain becomes the ninth European country for Opel Vauxhall Finance (OVF) to go live with FinnOne.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005757/en/
OVF is the automotive finance captive organization of Opel and Vauxhall, supported by Stellantis and BNP Paribas. OVF trades under strong local brands such as Opel Bank, Opel Financial Services and Vauxhall Finance. OVF has multiple operational branches across Europe, each operating under local bank licence or Financial Institution.
While FinnOne has been supporting businesses for Opel Vauxhall Finance in Europe since 2006, Spain is the latest country that will run OVF business using FinnOne. The OVF FinnOne partnership began in Italy and then moved on to Belgium, Netherlands, UK, France, Germany, Austria and Switzerland. The OVF portfolio includes a wide range of auto financing products, including consumer loans, leasing, insurance and service contracts.
Opel Vauxhall Finance wanted to utilize its core applications to achieve economies of scale. Nucleus Software FinnOne SRS (Strategic Retail Solution) is helping OVF in leveraging existing functionalities and aligning Spanish business processes to the OVF strategic applications rather than customizing and increasing scope & cost.
“With FinnOne going live in Spain, Opel Vauxhall Finance will be able to improve operational efficiency and align with the corporate strategic technology framework. With enhanced digitization, we will also be able to strengthen the collaboration framework with Opel/Vauxhall to increase the volume of financed/leased vehicles while at the same time raising retail margins across Europe,” says Alexandre Sorel, CEO of Opel Vauxhall Finance.
“We are proud to continue to bring value to our long-term partnership with Opel Vauxhall Finance (OVF). Spain is the ninth European country where FinnOne is supporting OVF in running their complex business. Having a common solution running across nine countries provides a competitive edge to OVF in terms of operational efficiency, uniform rollouts and standardization. We were able to go live despite the pandemic by meeting business commitments thanks to the coming together of OVF and Nucleus teams using our deep expertise in off-shore implementation methodology,” says Parag Bhise, CEO, Nucleus Software.
About Opel Vauxhall Finance:
OVF (Opel Vauxhall Finance) is the automotive finance captive organization of Opel and Vauxhall, supported by Stellantis and BNP Paribas, taken over from GM Financial in 2017. OVF trades under strong local brands such as Opel Bank, Opel Financial Services and Vauxhall Finance. OVF has multiple operational branches across Europe, each operating under local bank licence or Financial Institution. For IT Operations, everything is controlled from UK under the name Opel Vauxhall Finance.
Its portfolio includes a wide range of auto financing products, including consumer loans, leasing, insurance and service contracts as well as dealer financing. In Germany, OVF also offer money market accounts and fixed-term deposits directly to end-consumers, complementing our traditional automotive finance business.
OVF's primary goal is to meet the mobility needs of customers across Europe, while sustaining and developing the Opel and Vauxhall brands through competitive and attractive automotive finance solutions. Financing Opel and Vauxhall Brands dates back to 1920 when it opened its first office in London, helping people in the UK to finance their vehicles. In 1929 Opel Finanzierungsgesellschaft mbH was founded in Russelsheim, Germany, as the strategic finance partner for Opel.
About Nucleus Software:
Nucleus Software Exports Ltd. is a publicly traded (BSE: 531209, NSE: NUCLEUS) software product company that provides lending and transaction banking products to global financial leaders.
Nucleus Software powers the operations of more than 200 Financial Institutions in over 50 countries, supporting retail lending, corporate banking, cash management, mobile and internet banking, automotive finance and other business areas. Its products facilitate more than 26 million transactions each day, managing over US $200 billion of loans and enabling more than 200,000 users logging in daily.
For more information, please visit: www.nucleussoftware.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005757/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom